Sun Pharma acquires Organon for $11.75 billion in landmark deal. India's largest drugmaker will purchase the New Jersey-based pharmaceutical company for $14 per share in an all-cash transaction. The acquisition significantly strengthens Sun Pharma's global position, elevating it into the top 25 global pharmaceutical companies with combined revenues reaching $12.4 billion. Organon, spun off from Merck in 2021, specializes in women's health and biosimilars with over 70 products sold across 140 countries. The deal expands Sun Pharma's innovative medicines segment from 20% to 27% of total sales, reflecting the company's strategic focus on growth beyond generics. Sun Pharma shares surged more than 7% following the announcement, signaling investor confidence in the strategic move to scale operations in the critical U.S. pharmaceutical market.
